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Background
• Protocols for management of respiratory symptoms of COVID-19 are
well recognized but no clear-cut guidance on follow up of
neurological sequalae of the disease
• Neurologic complications are higher in critically ill ICU patients
• Patients with progressive neurological symptoms should be
monitored and risk factors treated
• Strong need to monitor the mental well being of patients in the
months following diagnosis of COVID-19

Objectives
• Review pathogenesis of neurologic symptoms in COVID-19
• Stages of recovery following COVID-19
• Case based discussions
• Follow up for COVID-19 long haulers

Poll Question- 1
How long after having symptomatic COVID-19 is a patient classified as
Long COVID?
A) 2 weeks
B) 4 weeks
C) 3 months
D) 6 months

Stages of recovery
●Acute COVID-19: COVID-19 symptoms up to 4 weeks after onset
●Ongoing symptomatic COVID-19: COVID-19 symptoms from 4 to 12
weeks following onset
●Post-COVID-19: symptoms develop during / after COVID-19, continue
for ≥ 12 weeks, not explained by alternative diagnosis
Stages reflect symptomatic recovery, not active viral infection and
infectivity
Long COVID is used for both symptomatic COVID-19 and post COVID
syndrome

Neurological complications in each stage
ACUTE COVID-19

ONGOING SYMPTOMATIC COVID-19

POST COVID-19

DELIRIUM

CONFUSION (11%)

BRAIN FOG (81%)
BLURRED VISION (30%)

CVA

SLEEP DISORDERS (36%)

NUMBNESS/TINGLING(60%)

DYSGEUSIA/ANOSMIA

DYSGEUSIA, ANOSMIA

DYSGEUSIA(59%), ANOSMIA(55%)

SEIZURE

HEADACHE (17%)

HEADACHE (68%) PAIN (43%)

CRITICAL ILLNESS
POLYNEUROPATHY/MYOPATHY

MYALGIA (55%)
DIZZINESS (47%)
TINNITUS (29%)

Why does the brain need so much O2?
• Muscles can store excess carbohydrates as an energy source; brain
has no reserve of energy.
• Uninterrupted blood flow provides glucose and O2.
• Homeostatic brain function is quickly lost without O2
• Gray matter > 2X O2 as white matter (highest in medial occipital lobe)
• Time lost is brain lost : CVA ~1.9 million neurons, and 14 billion
synapses are lost per minute

Neuropathogenesis
• Neurologic injury from systemic dysfunction and hypoxemia
• Renin-angiotensin system dysfunction
• Direct viral invasion of the nervous system causing cytopathic effects
• Immune response as a “double edged sword” with hyperactivation of
host immune response
a) Proinflammatory cytokines →cytokine storm→ damage BBB,
thrombophilia, complement & microglial activation ↑ stroke risk
b) Para infectious and postinfectious triggers
c) Presence of autoantibodies may cause higher thrombotic
complications

Role of angiotensin-converting enzyme 2 (ACE2) in
COVID-19 Critical Care volume 24, Article number: 422 (2020)
• ACE2 receptor acts as a doorway to COVID 19
• Both SARS-CoV-2 and SARS-CoV enter host cells via the angiotensinconverting enzyme 2 (ACE2) receptor.
• ACE2 is highly expressed in capillary rich organs such as lungs and
kidneys but also in the gut and brain while ACE receptors are
expressed in almost all tissues

Case presentation: Mrs. A

80 yr old F with HTN, DM, short term memory problems admitted with
COVID-19 pneumonia. Hospital course was prolonged due to delirium
where she was confused, agitated, refused to participate in physical
therapy, had poor appetite. Visitor restriction, lethargy and inability to
participate in rehab were factors that contributed to delayed recovery.
She was finally discharged after 3 weeks in the hospital.
Progressive functional and cognitive decline needing frequent
hospitalizations and finally death in 6 months

Poll Question-2
The 30-day mortality for COVID-19 patients with delirium is significantly
higher.
A) True
B) False

DELIRIUM
• Delirium: hyperactive, hypoactive state, or a mixture of both
• Hallmark- acute change in mentation/attention /disorganized thinking/easy
distractibility. Accompanied by perception disturbances with illusions,
delusions or hallucinations.
• Considered a marker of acute brain dysfunction, much like shock is
evidence for dysfunction of the cardiovascular system
• Longer length of stays, worse functional status at discharge, and a higher
30-day mortality rate 22% vs 3% those without delirium
• Prepare family for decisions like DNR, tube feeds, ventilator and end of life
care. Counsel them about need to consider patients QOL in these decisions

Poll question-3
Risk factor/s for delirium as a complication of COVID-19 is/are:
A) Underlying neurodegenerative illness
B) Cancer
C) Chronic kidney disease in the setting of CAD, DM or HTN
D) Smoking
E) All of the above

Tools to assess delirium in the ICU
• The Confusion Assessment Method-Intensive Care Unit (CAM-ICU)
Designed for non-verbal (i.e. mechanically ventilated) patients
• Found online at http://www.icudelirium.org/delirium.html.
• The Intensive Care Delirium Screening Checklist assesses eight
features of delirium: altered level of consciousness, inattention,
disorientation, hallucinations, psychomotor agitation/retardation,
inappropriate mood/speech, sleep/wake cycle disturbance, and
symptom fluctuation

CEREBROVASCULAR DISEASE
• 1-3 weeks after onset of COVID-19 symptoms
• Ischemic stroke has ranged from 0.4 to 2.7%
• Intracranial hemorrhage has ranged from 0.2 to 0.9%
• Cerebral venous thrombosis: estimated frequency 0.08%
• Increased in vascular risk factors, thrombophilia predisposing to
hypercoagulability, cardioembolic source from myocarditis
• Management should follow the same routine stroke protocol with
thrombolytics and thrombectomies as appropriate

Vaccination after COVID-19 infection
• What is the ideal time to get vaccination for someone who has had
COVID 19?

Case presentation: Nurse B

• 42 yr old F RN working on a COVID unit. Tested positive for COVID-19
in March,2020. Had mild symptoms of fever, anosmia and fatigue.
Able to return to work in 2 weeks. Persistent fatigue, insomnia and
anosmia for months. She received vaccination in Jan,2021. Symptoms
improved with vaccine.
• “It was like a revelation,”. The brain fog cleared completely, muscle
aches were gone, joint pains were less intense, and I suddenly had
much more energy. It felt, “like the old me.”

Vaccination eases symptoms of long COVID
• Vaccinate after coming out of quarantine
• 57% reported overall improvement in symptoms, 19%
reported an overall deterioration
• Vaccine may stop harmful immune response in longhaulers or resets immune system.
• Post monoclonal Ab, wait 90 days after recovery

Case presentation: Mr. C
30 yr old M high school Math teacher had mild symptoms of anosmia
and headache for 2 days. Did not need hospitalization or any
medications. Ongoing fatigue for the past 12 weeks, inability to focus,
having short term memory lapses, gets short of breath and tachycardia
with walking to the school parking lot. Unable to sit in front of the
computer screen for very long. Easily irritable when children ask him
questions. Unable to grade assignments on time. Does not have any
more sick leave left.

COVID long haulers
• “long haulers” have persistent, debilitating symptoms despite mild illness
at onset which did not need hospitalization
• 10 most frequent neurologic symptoms: non-specific cognitive complaints,
“brain fog” (81%), headache (68%), numbness/tingling (60%), dysgeusia
(59%), anosmia (55%), myalgia (55%), dizziness (47%), pain (43%), blurred
vision (30%), and tinnitus (29%).
• Half of the patients had abnormal neurologic exam, with abnormalities on
short-term memory and attention functions being prominent.
• Prominent fatigue and cognitive complaints resemble those after mild
traumatic brain injury, and in patients with myalgic encephalomyelitis/
chronic fatigue syndrome (ME/CFS)

Follow up
• For patients with persistent symptoms ≥12 weeks, recommend evaluation
in a specialized outpatient COVID-19 recovery clinic, or a multi disciplinary
subspecialty clinic
• Opportunity to review advanced care planning
• Comprehensive history of acute COVID-19 illness, duration and severity of
symptoms, types of complications (eg, thromboembolism, any kidney
injury, supplemental O2 [including the need mechanical ventilation],
cardiac complications, delirium), COVID-19 results, and treatment
strategies
• Labs based on symptoms, inflammatory markers are not monitored
• WHO guidelines to remove isolation based on active symptoms

Society of Critical Care Medicine screening tools to detect long-term cognition, mental health,
and physical function after critical illness
Domain
Screening test
Comments
Cognition

Montreal Cognitive Assessment
(MoCA)

Mild cognitive impairment score
of 18 - 25, moderate as 10 -17,
and severe < 10

Anxiety

HADS

A score of 8 or > on the anxiety
or depression sub-scale is used
to identify symptoms of
clinically significant anxiety or
depression

Depression

HADS

PTSD

IES-R or the abbreviated IES-6

Can be evaluated as a %
predicted against available
normative data

Physical function

6-min walk and/or EuroOol-5D5L

Includes assessments of
mobility, self-care, and usual
activities, in addition to pain
and anxiety/depression

Complications in children
What severe complication of COVID-19 should you
consider when a child with exposure to COVID-19
presents with fever, rash, confusion?

Multisystem Inflammatory Syndrome in Children MIS-C
• Age <21 yrs, lab evidence of inflammation, evidence of clinically
severe illness requiring hospitalization, with multisystem (>2) organ
involvement (cardiac, renal, respiratory, hematologic, gastrointestinal,
dermatologic or neurological); AND
• No alternative plausible diagnoses; AND
• Fever >38.0°C for ≥24 hours, or report of subjective fever lasting ≥24
hours
• Elevated CRP, ESR, fibrinogen, procalcitonin, d-dimer, ferritin, LDH, or
IL-6, elevated neutrophils, reduced lymphocytes and low albumin
• Positive for current or recent SARS-CoV-2 infection by RT-PCR,
serology, or antigen test; or COVID-19 exposure within the 4 weeks
prior to the onset of symptoms

Thank you
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